Stock 4563 ANGES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials AnGes, Inc.

Equities

4563

JP3127700007

Biotechnology & Medical Research

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-04-26 am EDT 		5-day change 1st Jan Change
49 JPY 0.00% Intraday chart for AnGes, Inc. -2.00% -31.94%
Jan. 19 Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease MT
Jan. 18 Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 35,197 68,353 165,659 58,780 20,914 14,229
Enterprise Value (EV) 1 29,413 58,313 154,122 40,881 11,033 10,430
P/E ratio -10.5 x -17.8 x -35.2 x -4.14 x -1.29 x -1.83 x
Yield - - - - - -
Capitalization / Revenue 57.7 x 210 x 4,248 x 918 x 312 x 93.6 x
EV / Revenue 48.2 x 179 x 3,952 x 639 x 165 x 68.6 x
EV / EBITDA -9.62 x -17.9 x -27.6 x -3.1 x -0.82 x -1.18 x
EV / FCF -20.2 x -53.8 x -1,382 x -5.69 x -2.11 x -1.14 x
FCF Yield -4.95% -1.86% -0.07% -17.6% -47.3% -88%
Price to Book 4.6 x 5.67 x 5.07 x 1.52 x 0.72 x 0.55 x
Nbr of stocks (in thousands) 96,961 106,969 133,059 153,072 171,424 197,620
Reference price 2 363.0 639.0 1,245 384.0 122.0 72.00
Announcement Date 3/29/19 3/30/20 3/31/21 3/31/22 3/31/23 3/29/24
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 610 326 39 64 67 152
EBITDA 1 -3,058 -3,263 -5,593 -13,207 -13,415 -8,860
EBIT 1 -3,065 -3,270 -5,600 -15,632 -16,316 -11,968
Operating Margin -502.46% -1,003.07% -14,358.97% -24,425% -24,352.24% -7,873.68%
Earnings before Tax (EBT) 1 -3,002 -3,750 -4,205 -13,734 -14,716 -7,470
Net income 1 -2,996 -3,750 -4,209 -13,675 -14,714 -7,437
Net margin -491.15% -1,150.31% -10,792.31% -21,367.19% -21,961.19% -4,892.76%
EPS 2 -34.45 -35.81 -35.32 -92.85 -94.29 -39.29
Free Cash Flow 1 -1,457 -1,085 -111.5 -7,179 -5,220 -9,178
FCF margin -238.79% -332.75% -285.9% -11,217.19% -7,790.3% -6,038.16%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/29/19 3/30/20 3/31/21 3/31/22 3/31/23 3/29/24
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 S1 2021 Q3 2022 Q1 2022 S1 2022 Q3 2023 Q1 2023 S1 2023 Q3
Net sales 1 16 23 21 15 31 14 16 51 51
EBITDA - - - - - - - - -
EBIT 1 -1,766 -7,540 -4,623 -3,543 -9,124 -3,331 -3,036 -5,951 -3,256
Operating Margin -11,037.5% -32,782.61% -22,014.29% -23,620% -29,432.26% -23,792.86% -18,975% -11,668.63% -6,384.31%
Earnings before Tax (EBT) 1 -1,890 -7,436 -4,518 -2,934 -7,420 -2,753 -2,898 -4,777 55
Net income 1 -1,896 -7,450 -4,502 -2,938 -7,425 -2,769 -2,911 -4,830 32
Net margin -11,850% -32,391.3% -21,438.1% -19,586.67% -23,951.61% -19,778.57% -18,193.75% -9,470.59% 62.75%
EPS 2 -16.58 -52.70 -29.55 -19.20 -48.51 -18.09 -15.91 -26.09 0.4000
Dividend per Share - - - - - - - - -
Announcement Date 7/30/20 8/6/21 11/5/21 5/10/22 8/9/22 11/8/22 5/10/23 8/9/23 11/8/23
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 5,784 10,040 11,537 17,899 9,881 3,799
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -1,457 -1,085 -112 -7,179 -5,220 -9,178
ROE (net income / shareholders' equity) -52.8% -37.9% -18.8% -38.4% -42.6% -26.3%
ROA (Net income/ Total Assets) -31.9% -19.9% -13.8% -23.3% -24.2% -22.1%
Assets 1 9,394 18,875 30,592 58,653 60,800 33,661
Book Value Per Share 2 78.90 113.0 246.0 252.0 170.0 132.0
Cash Flow per Share 2 59.00 93.90 86.70 117.0 61.80 21.00
Capex 1 50 6 80 80 19 89
Capex / Sales 8.2% 1.84% 205.13% 125% 28.36% 58.55%
Announcement Date 3/29/19 3/30/20 3/31/21 3/31/22 3/31/23 3/29/24
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ANGES, INC. Stock AnGes, Inc.
-31.94% 62.66M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 4563 Stock
  4. Financials AnGes, Inc.